Can you describe a patient example and tumor type where whole exome sequencing (WES) with NGS generated an effective treatment option that would not have emerged empirically without NGS?

Can you describe a patient example and tumor type where whole exome sequencing (WES) with NGS generated an effective treatment option that would not have emerged empirically without NGS?

Can you describe a specific patient example and tumor type where whole exome sequencing (WES) with NGS generated a safe and effective treatment option that would not have emerged empirically without NGS?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof. Jean-Yves Blay, MD, PhD

Prof. Jean-Yves Blay, MD, PhD

Professor of Medicine
Université Claude Bernard
Lyon, France
Scientific Director
Canceropole Lyon Rhône Alpes